Shares of ShockWave Medical SWAV moved higher by 0.6% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 98.21% year over year to ($0.01), which beat the estimate of ($0.41).
Revenue of $55,908,000 higher by 443.53% year over year, which beat the estimate of $45,170,000.
Guidance
Shockwave Medical raised FY21 sales guidance from $195 million-$205 million to $218 million-$223 million.
Details Of The Call
Date: Aug 09, 2021
Time: 08:30 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/m4mofn4j
Technicals
Company's 52-week high was at $203.74
Company's 52-week low was at $50.08
Price action over last quarter: Up 15.87%
Company Profile
ShockWave Medical Inc a medical device company focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated. Its intravascular lithotripsy technology is used in the treatment of calcified plaque. Geographically, the company generates its revenue from the United States.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
